- Home
- UAA vs ADPT Comparison
UAA vs ADPT Comparison
Compare UAA & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAA
- ADPT
- Stock Information
- Founded
- UAA 1996
- ADPT 2009
- Country
- UAA United States
- ADPT United States
- Employees
- UAA N/A
- ADPT N/A
- Industry
- UAA Apparel
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UAA Consumer Discretionary
- ADPT Health Care
- Exchange
- UAA Nasdaq
- ADPT Nasdaq
- Market Cap
- UAA 2.2B
- ADPT 2.0B
- IPO Year
- UAA N/A
- ADPT 2019
- Fundamental
- Price
- UAA $4.84
- ADPT $14.40
- Analyst Decision
- UAA Hold
- ADPT Strong Buy
- Analyst Count
- UAA 20
- ADPT 9
- Target Price
- UAA $6.91
- ADPT $13.22
- AVG Volume (30 Days)
- UAA 11.3M
- ADPT 2.1M
- Earning Date
- UAA 11-06-2025
- ADPT 11-06-2025
- Dividend Yield
- UAA N/A
- ADPT N/A
- EPS Growth
- UAA N/A
- ADPT N/A
- EPS
- UAA 0.23
- ADPT N/A
- Revenue
- UAA $5,114,713,000.00
- ADPT $205,216,000.00
- Revenue This Year
- UAA N/A
- ADPT $32.76
- Revenue Next Year
- UAA $2.72
- ADPT $15.81
- P/E Ratio
- UAA $21.40
- ADPT N/A
- Revenue Growth
- UAA N/A
- ADPT 21.60
- 52 Week Low
- UAA $4.72
- ADPT $4.27
- 52 Week High
- UAA $11.89
- ADPT $15.26
- Technical
- Relative Strength Index (RSI)
- UAA 40.49
- ADPT 60.53
- Support Level
- UAA $4.90
- ADPT $14.04
- Resistance Level
- UAA $5.15
- ADPT $15.26
- Average True Range (ATR)
- UAA 0.14
- ADPT 0.73
- MACD
- UAA 0.04
- ADPT 0.05
- Stochastic Oscillator
- UAA 33.72
- ADPT 69.09
About UAA Under Armour Inc.
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).